Enrollment is now open for the 30-Day Hospital Readmission (HRA) program
New in 2020, the 30-Day Hospital Readmission (HRA) benchmark will help providers to better understand the frequency and reason for re-hospitalization within the first 30 days of home infusion therapy for patients with congestive heart failure (CHF) receiving milrinone or dobutamine; and in parenteral nutrition patients referred for home therapy. These populations were selected for the higher level of complexity associated with the transition of care from hospital to home, and high acuity. This metric is voluntary, meaning if you participate in Patient Satisfaction and Status at Discharge, you do not need to report.
Download the 30-day Hospital Re-Admission Guide
Additional documents will be shared as soon as they are available.